Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Depreciation and Depletion (2016 - 2017)

Historic Depreciation and Depletion for Avalo Therapeutics (AVTX) over the last 4 years, with Q4 2017 value amounting to $4906.0.

  • Avalo Therapeutics' Depreciation and Depletion fell 2319.97% to $4906.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $21956.0, marking a year-over-year decrease of 1824.55%. This contributed to the annual value of $200000.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Avalo Therapeutics reported Depreciation and Depletion of $4906.0 as of Q4 2017, which was down 2319.97% from $5361.0 recorded in Q3 2017.
  • In the past 5 years, Avalo Therapeutics' Depreciation and Depletion ranged from a high of $7881.0 in Q4 2014 and a low of $4906.0 during Q4 2017
  • Over the past 4 years, Avalo Therapeutics' median Depreciation and Depletion value was $6148.0 (recorded in 2015), while the average stood at $6169.3.
  • As far as peak fluctuations go, Avalo Therapeutics' Depreciation and Depletion soared by 2299.33% in 2016, and later crashed by 2397.9% in 2017.
  • Over the past 4 years, Avalo Therapeutics' Depreciation and Depletion (Quarter) stood at $7881.0 in 2014, then dropped by 21.99% to $6148.0 in 2015, then rose by 3.9% to $6388.0 in 2016, then fell by 23.2% to $4906.0 in 2017.
  • Its Depreciation and Depletion was $4906.0 in Q4 2017, compared to $5361.0 in Q3 2017 and $5859.0 in Q2 2017.